我院大肠埃希氏菌、肺炎克雷伯菌耐药变迁的影响因素与AMS干预研究

我院大肠埃希氏菌、肺炎克雷伯菌耐药变迁的影响因素与AMS干预研究

赵翠红

汉中市中心医院

收稿日期:2019-02-21 修回日期:2019-03-06 出版日期:2019-03-25
基金资助:
陕西省卫生厅科研基金中标项目（项目编号：2012E8）

The Study on Influence Factors of Drug Resistance Changes of Escherichia Coli and Klebsiella Pneumoniae and Intervention of Antimicrobial Stewardship in Our Hospital

ZHAO Cuihong

The study on influence factors ofdrug resistance changes of Escherichia coli and Klebsiella pneumonia and intervention of antimicrobial stewardship in our hospital

Received:2019-02-21 Revised:2019-03-06 Online:2019-03-25

摘要/Abstract

摘要： 目的：系统研究我院大肠埃希氏菌、肺炎克雷伯菌耐药性变迁与抗菌药物使用频度（DDDs）相关性，通过抗菌药物科学化管理（AMS），有效遏制细菌耐药。方法：以季度为统计时间段，采用回顾性分析方法，分别统计我院2016年1季度至2018年1季度大肠埃希氏菌、肺炎克雷伯菌耐药率和抗菌药物DDDs，通过SPSS 20.0统计学软件处理数据，分析其相关性及差异性。结果：大肠埃希氏菌耐药性与β-内酰胺酶抑制剂类、头霉素类抗菌药物DDDs呈高度正相关，相关系数（r）分别为0.81、0.82（P<0.05）；与抗菌药物总DDDs呈中度正相关，r=0.72（P<0.05）。肺炎克雷伯菌与β-内酰胺酶抑制剂类抗菌药物DDDs呈高度正相关，r=0.80（P<0.05）；与头霉素类及抗菌药物总DDDs呈中度正相关，r分别为0.69、0.71（P<0.05）。通过AMS干预后，β-内酰胺酶抑制剂类、头霉素类抗菌药物DDDs分别下降43.03%、28.63%，大肠埃希氏菌、肺炎克雷伯菌耐药率分别下降1.98%、3.98%。结论：我院大肠埃希氏菌、肺炎克雷伯菌耐药性与β-内酰胺酶抑制剂类、头霉素类抗菌药物DDDs有相关性，随着DDDs增加耐药率日渐增长，AMS干预使β-内酰胺酶抑制剂类、头霉素类抗菌药物DDDs下降，成效显著，同时大肠埃希氏菌、肺炎克雷伯菌耐药性得到有效控制。

Abstract: Objective：To systematically study the correlation between drug resistance changes of Escherichia coli and Klebsiella pneumoniae and the defined daily doses (DDDs)， through the antimicrobial stewardship （AMS），effectively curb bacterial drug resistance. Methods：Based on the quarterly statistical period， the retrospective analysis method was used to calculate the resistance rate of Escherichia coli and Klebsiella pneumoniae and antibacterial DDDs from the first quarter of 2016 to the first quarter of 2018. The data and the significance of difference analysis used the SPSS 20 software. Results： The drug resistance of Escherichia coli was highly correlated with the DDDs of enzyme inhibitors and cephamycins， and the correlation coefficient were 0.81 and 0.82（P<0.05）. The drug resistance of Escherichia coli was moderately positively correlated with the DDDs of antibiotics， and the correlation coefficient was 0.72（P<0.05）.The drug resistance of Klebsiella pneumoniae was highly correlated with the DDDs of enzyme inhibitors， and the correlation coefficient was 0.80（P<0.05）. The drug resistance of Klebsiella pneumoniae was moderately positively correlated with the DDDs of antibiotics and cephamycins， and the correlation coefficient were 0.69 and 0.71（P<0.05）. After intervention of antimicrobial stewardship in our hospital， the DDDs of β-lactamase inhibitors and cephamycins decreased by 43.03% and 28.63% respectively，and the drug resistance rates of Escherichia coli and Klebsiella pneumoniae decreased by 1.98% and 3.98% respectively.Conclusion： The drug resistance of Escherichia coli and Klebsiella pneumoniae is positively correlated with the DDDs of β-lactamase inhibitors and cephamycins. With the increase of DDDs， the rate of drug resistance is increasing.After intervention of antimicrobial stewardship in our hospital，the DDDs of β-lactamase inhibitors and cephamycins were decreased， and the drug resistance of Escherichia coli and Klebsiella pneumoniae was effectively controlled.

赵翠红. 我院大肠埃希氏菌、肺炎克雷伯菌耐药变迁的影响因素与AMS干预研究[J]. .

ZHAO Cuihong. The Study on Influence Factors of Drug Resistance Changes of Escherichia Coli and Klebsiella Pneumoniae and Intervention of Antimicrobial Stewardship in Our Hospital[J]. .

参考文献

[1]陈晓凤,李方兰.精细化管理在多药耐药菌控制管理中的应用[J].当代护士(综合版),2014,(8):26-27.
[2]张文丽.多药耐药菌感染防控管理对策[J].中国临床研究,2013,26(5):522,524.
[3] World Health Organization．WHO multi—country survey reveals widespread public misunderstanding about antibiotic resistanee [EB/OL]. [2016-10-25] http:// www. Who .int /mediacentre /news /releases / 2015/ antibiotic ． Resistance /en /．
[4]胡付品,郭燕,朱德妹,等.2016年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2017,17(5):481-491.
[5]Clinical and Laboratorv Standads Institute．Performance standards for antimicrobial susceptibility testing [S]．Twenty—sixth informational supplement,2016,M100-S26．
[6]梁健,韦祎.第三代头孢菌素类的使用量与鲍曼不动杆菌对其耐药率的相关性研究[J]. 实用预防医学,2014,10(21):1173-1176.
[7] WHO collaborating center for drug statistics methodology.ATC ／ DDD index 2008 [EB／OL].http://www.whocc.no /atcddd /2014-11-20.
[8]蒋陆霞贾秀芹庞峰,等.2009—2014年我院抗菌药物临床应用对鲍曼不动杆菌耐药性变迁的影响[J]. 国际医药卫生导报,2016,(22):1344.
[9]蒋建清,饶媚,陈东风,等.我院抗菌药物用量与常见革兰氏阴性菌耐药相关性分析[J].海峡药学,2016,(28):117.
[10]李朝霞.抗生素的过量使用与细菌耐药性关系分析[J].世界最新医学信息文摘(电子版),2014,(13):147-148.
[11]张青,马慧娜.大肠埃希菌生物膜形成与耐药机制的研究进展[J]. 中国抗生素杂志, 2018,43(5): 497-501.
[12]刘瑾.大肠杆菌外膜蛋白F的表达与鉴定[D].郑州大学,2012:1-66.
[13]贾文祥.微生物生物膜研究的新进展[J].微生物学免疫学进展,2012,40(5):1-9.
[14]崔鹏,许涛,张文宏,等.细菌持留与抗生素表型耐药机制[J].遗传,2016,38(10):859-871.
[15]Mclaughlin M , Advincula M R , Malczynski M , et al. Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae[J]. Antimicrobial Agents and Chemotherapy, 2013, 57(10):5131-5133.
[16]陈蔚, 涂春莲, 俞春芳, 等. 2010—2011年我院抗菌药物使用量与细菌耐药分析[J]. 安徽医药, 2013, 17(2):325-327.
[17]陈东科,周海健.耐碳青霉烯类抗生素肺炎克雷伯菌种群结构和耐药机制研究[J].中国抗生素杂志,2018(43)：507.
[18]Hamzaoui Z , Ocampo-Sosa A , Martinez M F , et al. Role of association of OmpK35 and OmpK36 alteration and, blaESBL, and/or blaAmpC in conferring carbapenem resistance among non-producing carbapenemase- Klebsiella pneumoniae[J]. Int J of Antimicrobial Agents, 2018,4. pii:S0924-8579(18)30098-0.
[19]Pages J M , Lavigne J P , Véronique Leflon-Guibout, et al. Efflux Pump, the Masked Side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates[J]. PLOS ONE, 2009, 4(3):e4817.
[20] European Centre for Disease Prevention and Control European．Surveillance report(2012) surveillance of antimicrobial consumption in Europe:2014[EB/OL].[2016-12-01].https://ecdc.europa.eu/sites/portal/files/media /en/publications/publications/antimicrobial-consumption-europe-e- sac-net-2012.pdf.
[21]Mclaughlin M , Advincula M R , Malczynski M , et al. Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae[J]. Antimicrobial Agents and Chemotherapy, 2013, 57(10):5131-5133.

快速检索引用检索图表检索高级检索